Welcome to our dedicated page for Medirom Healthcare Technologies SEC filings (Ticker: MRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for the numbers behind MEDIROM’s fast-growing Relaxation Salon network or the R&D spend powering its self-charging MOTHER Tracker? Start here. This page aggregates every MEDIROM SEC document—10-K annual report, 10-Q quarterly earnings, 8-K material events, and Form 4 insider trades—in real time from EDGAR.
Our AI quickly answers the questions investors type into Google: “MEDIROM insider trading Form 4 transactions,” “How is digital healthcare revenue trending in the latest MEDIROM quarterly earnings report 10-Q filing,” or “Where does the proxy statement detail executive compensation for tech leadership?” Instead of combing through hundreds of pages, you’ll receive AI-powered summaries that translate accounting language into plain English and spotlight segment revenue, device shipment metrics, and salon traffic comps.
Use the platform to:
- Track MEDIROM Form 4 insider transactions in real-time and spot buying ahead of product launches.
- Compare salon same-store sales between 10-Q filings with one-click charts.
- See 8-K material events explained, from new corporate wellness contracts to sensor technology partnerships.
- Dive into the annual report 10-K simplified to understand how digital preventative healthcare margins stack up against luxury beauty.
Every filing is time-stamped, searchable, and paired with expert commentary, so you can focus on decisions, not document hunting. Understanding MEDIROM SEC documents with AI has never been this straightforward.
On 26 June 2025, MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) disclosed via Form 6-K that its Board approved a new allotment of stock options under the 2024 Equity Incentive Compensation Plan. The options will be formally granted around 18 July 2025 at an issue price of ¥2 per option and an exercise price of US$1.74 per share, or the ADS closing price on the allotment date if higher. The exercise window runs from 18 July 2026 through 17 July 2030.
The awards are performance-linked. Holders may exercise only if, during any fiscal year 2026-2028, adjusted consolidated revenue—excluding Digital Preventative Healthcare and sales of directly-owned salons—exceeds JPY 10 billion, a level that is approximately 69 % above FY-2024. Additionally, recipients must remain in service; post-termination exercises are limited to 12 months unless departure is for just cause such as retirement or tenure expiry.
Total options approved for allotment comprise 207,000 for 14 directors/statutory auditors, 87,000 for 16 employees, and 106,000 for seven external collaborators. The instruments include customary forfeiture provisions and anti-dilution adjustments for stock splits.
No immediate financial impact is recorded, but the plan aligns management incentives with aggressive topline growth targets while introducing potential future dilution should the hurdles be met.
MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) submitted a routine Form 6-K on 20 June 2025. The filing simply furnishes—rather than files—a press release (Exhibit 99.1) that updates the Company’s Key Performance Indicators (KPIs) for May 2025. Because the information is “furnished,” it is not subject to Section 18 liability and will not be automatically incorporated by reference into other SEC documents. No financial statements, earnings results, or transaction details are included, and the Company confirms it continues to report under Form 20-F.
FAQ
What is the current stock price of Medirom Healthcare Technologies (MRM)?
What is the market cap of Medirom Healthcare Technologies (MRM)?
What are the core business segments of MEDIROM Healthcare Technologies Inc.?
How does the company generate revenue?
What makes the Relaxation Salon segment significant?
What innovative health-tech products does MEDIROM offer?
How does MEDIROM integrate digital health into its services?
Where does MEDIROM primarily operate?
How does MEDIROM differentiate itself from its competitors?
Which industries benefit from MEDIROM's digital health solutions?
